Table 1 shows demographic and clinical characteristics of 2293 women who were diagnosed with stages I-III breast cancer from 2013 to 2017; reported to the California or Georgia SEER registries; linked to a genetic test result; had HR-positive, HER2-negative disease (n = 1451) or TNBC (n = 842); and received chemotherapy as first-course treatment. Here, ERBB2 is linked to breast carcinoma.